Marc Rivière joined the Montreal-based TVM Capital Life Science team in 2013 after twenty years of international drug development preceded by ten years of medical and public health practice in Europe and the Middle East.
Marc’s expertise encompasses all aspects of drug development in different clinical indications from pre-clinical development to post marketing surveillance. At TVM Capital Life Science, he focuses on evaluation of deal opportunities and investment management for therapeutics. He also works closely with the firm’s strategic partner Eli Lilly & Co. and its drug development division Chorus. Prior to joining TVM Capital Life Science, Marc was Vice-President, Axcan Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance. He also served as Senior Vice President, Clinical Development at Caprion Pharmaceuticals, Chief Medical Officer for Bioniche Life Sciences Inc., Managing Director of Xenon Genetics Inc., Vice President of Clinical Affairs, Aeterna Labs and Executive Vice President and Regional Director, Quintiles Inc (previously Benefit International S.A.).
Marc received his Tropical Disease Medicine Certification from Université Bordeaux II, France and Medicine Doctorate from Université Paul Sabatier, Toulouse, France.